Effect of liver function on clinical outcomes in patients with unresectable hepatocellular carcinoma treated with first-line atezolizumab-bevacizumab: an Asia-Pacific multicenter retrospective analysis.
INTRODUCTION AND OBJECTIVES Atezolizumab+bevacizumab (atezo-bev) is the standard first-line therapy for unresectable hepatocellular carcinoma (uHCC), but pivotal trials were limited to patients with preserved liver function. Therefore, this study aims to evaluate the prognostic effect of Child-Pugh (CP) class and Album...